Orforglipron
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 1400
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Orforglipron Dose 1 (Study GZP1) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 2 (Study GZP1) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 3 (Study GZP1) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 4 (Study GZP1) | n/r | n/r | n/r | n/r |
| Placebo (Study GZP1) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 1 (Study GZP2) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 2 (Study GZP2) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 3 (Study GZP2) | n/r | n/r | n/r | n/r |
| Orforglipron Dose 4 (Study GZP2) | n/r | n/r | n/r | n/r |
| Placebo (Study GZP2) | n/r | n/r | n/r | n/r |
Not shown
- Orforglipron Dose 1 (Study GZP1): endpoint not reported
- Orforglipron Dose 2 (Study GZP1): endpoint not reported
- Orforglipron Dose 3 (Study GZP1): endpoint not reported
- Orforglipron Dose 4 (Study GZP1): endpoint not reported
- Placebo (Study GZP1): endpoint not reported
- Orforglipron Dose 1 (Study GZP2): endpoint not reported
- Orforglipron Dose 2 (Study GZP2): endpoint not reported
- Orforglipron Dose 3 (Study GZP2): endpoint not reported
- Orforglipron Dose 4 (Study GZP2): endpoint not reported
- Placebo (Study GZP2): endpoint not reported